Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Picard Medical, Inc. ( (PMI) ) has issued an update.
On January 13, 2026, Picard Medical launched the Cruxx to MedTech Podcast series in collaboration with advisory firm Cruxx, using patient survival narratives and executive commentary to spotlight the SynCardia Total Artificial Heart and its next-generation, fully implantable Emperor device. The series underscores the differentiated role of SynCardia’s platform as a potential alternative to heart transplantation amid a global shortage of donor hearts, aiming to raise awareness of the technology’s real-world impact and highlight the company’s commercial opportunity and strategic positioning in advanced cardiac care.
The most recent analyst rating on (PMI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down primarily by very weak financial performance—deep unprofitability and sustained negative operating cash flow—alongside bearish technical trend signals (below key moving averages and negative MACD). Corporate events provide some support via improved liquidity and encouraging product milestones, but they do not yet offset the high ongoing funding risk implied by current losses and cash burn.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, a Tucson, Arizona–based leader in total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that fully replaces the function of a failing human heart, and it is the first artificial heart approved by both the U.S. FDA and Health Canada, remaining the only commercially available artificial heart in the U.S. and Canada, with more than 2,100 implants performed in 27 countries.
Average Trading Volume: 1,917,466
Technical Sentiment Signal: Strong Sell
For an in-depth examination of PMI stock, go to TipRanks’ Overview page.